Marshall Wace, LLP Inhibrx, Inc. Transaction History

Marshall Wace, LLP

  • $72.2 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$32.76 - $39.56 $1.43 Million - $1.73 Million
43,678 New
43,678 $1.53 Million
Q3 2023

Nov 14, 2023
BUY
$15.75 - $26.31 $1.44 Million - $2.41 Million
91,550 Added 782.95%
103,243 $1.89 Million
Q2 2023

Aug 14, 2023
BUY
$16.96 - $27.82 $198,313 - $325,299
11,693 New
11,693 $303,000
Q4 2022

Feb 14, 2023
BUY
$20.18 - $33.33 $635,266 - $1.05 Million
31,480 New
31,480 $775,000
Q2 2021

Aug 13, 2021
BUY
$14.69 - $27.52 $177,425 - $332,386
12,078 New
12,078 $332,000

Others Institutions Holding INBX

# of Institutions
2
Shares Held
25.3K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email